Market Overview

UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT for NewLink Genetics

Related NLNK
Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines
These 4 Charts Highlight Twitter Sentiment For Today's Movers
Making Money With Charles Payne: 10/24/14 (Fox Business)

In a company update published earlier today, Cantor Fitzgerald L.P. reiterated its Buy rating for NewLink Genetics Corporation (NASDAQ: NLNK) and raised its price target from $15.00 to $18.00.

Cantor Fitzgerald went on to say “We have identified what we believe to be critical success factors for a cancer immunotherapy company and further believe that NewLink meets these criteria. The company has identified appropriate clinical settings with which to test its technology (modest disease burden, consistent booster dosing), has a robust trial design, is addressing critical unmet medical needs, and has a scalable, financially reasonable manufacturing process and technology. Additionally, the stage and depth of NewLink's clinical program is compelling, in our view, and there are multiple opportunities for milestone updates over the next 24 months. We are particularly encouraged by the Phase II HyperAcute Pancreas study as two- and three-year disease free and overall survival showed a strong and sustained response to the vaccine in a statistically significant manner.”

NewLink Genetics Corporation closed yesterday at $12.41.

Latest Ratings for NLNK

DateFirmActionFromTo
Nov 2014Stifel NicolausMaintainsBuy
Oct 2014Cantor Fitzgerald
Sep 2014Mizuho SecuritiesInitiates Coverage onBuy

View More Analyst Ratings for NLNK
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (NLNK)

Around the Web, We're Loving...

Get Benzinga's Newsletters